Next Article in Journal
Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis
Next Article in Special Issue
Nutrition and Liver Disease
Previous Article in Journal
Associations between Nut Consumption and Health Vary between Omnivores, Vegetarians, and Vegans
Previous Article in Special Issue
Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Nutrients 2017, 9(11), 1222; doi:10.3390/nu9111222

Nutritional Therapies in Congenital Disorders of Glycosylation (CDG)

Metabolic Center, University Hospitals Leuven, B-3000 Leuven, Belgium
Department of Development and Regeneration, Faculty of Medicine, KU Leuven, B-3000 Leuven, Belgium
Department of Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, B-3000 Leuven, Belgium
Hayward Genetics Center, Tulane University School of Medicine, New Orleans, LA 70112, USA
Author to whom correspondence should be addressed.
Received: 16 October 2017 / Revised: 1 November 2017 / Accepted: 1 November 2017 / Published: 7 November 2017
(This article belongs to the Special Issue Nutrition and Liver Disease)
View Full-Text   |   Download PDF [225 KB, uploaded 7 November 2017]


Congenital disorders of glycosylation (CDG) are a group of more than 130 inborn errors of metabolism affecting N-linked, O-linked protein and lipid-linked glycosylation. The phenotype in CDG patients includes frequent liver involvement, especially the disorders belonging to the N-linked protein glycosylation group. There are only a few treatable CDG. Mannose-Phosphate Isomerase (MPI)-CDG was the first treatable CDG by high dose mannose supplements. Recently, with the successful use of d-galactose in Phosphoglucomutase 1 (PGM1)-CDG, other CDG types have been trialed on galactose and with an increasing number of potential nutritional therapies. Current mini review focuses on therapies in glycosylation disorders affecting liver function and dietary intervention in general in N-linked glycosylation disorders. We also emphasize now the importance of early screening for CDG in patients with mild hepatopathy but also in cholestasis. View Full-Text
Keywords: galactose; mannose; congenital disorders of glycosylation (CDG); treatment; glycosylation; diet galactose; mannose; congenital disorders of glycosylation (CDG); treatment; glycosylation; diet
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Witters, P.; Cassiman, D.; Morava, E. Nutritional Therapies in Congenital Disorders of Glycosylation (CDG). Nutrients 2017, 9, 1222.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top